Lupin launches generic ciprofloxacin suspension in the US

Lupin Pharmaceuticals Inc, the US subsidiary of pharma major Lupin Ltd, has launched its ciprofloxacin for oral suspension, 5 gm/100 mL (250 mg/5 mL) and 10 gm/100 mL (500 mg/5 mL) in the US having receieved fina; approval from the FDA earlier.
 
Lupin's ciprofloxacin oral suspension is the generic equipvalent of Bayer Healthcare's Cipro oral suspension. It is indiacted for the treatment of infections caused by susceptible isolates of the designated microorganism in various conditions and patient populations.
 
Lupin, which is the first applicant to file an ANDA for Cipro oral suspension, is entitled to 180 days of marketing exclusivity. Cipro oral suspension had annual US sales of $ 8.6 million, according to IMS MAT March 2014.